Men make up the majority of people with methamphetamine use disorder in most population studies, and the general features of meth addiction that the clinical literature describes are largely drawn from male populations. But understanding the specific patterns, risk profiles, and clinical considerations that are most relevant to men in meth recovery requires looking past this majority-population framing to the features that are specifically or disproportionately relevant to men. The epidemiology of meth in men is not uniform; it varies significantly by geography, by social context, and by whether the person is part of the population of gay, bisexual, and other men who have sex with men (MSM), where meth use patterns, co-occurring health risks, and treatment considerations are distinct in clinically important ways.
As NIDA documents in its sex differences research, men are more likely than women to use almost all types of illicit drugs, and illicit drug use is more likely to result in emergency department visits or overdose deaths for men than for women. Men are more likely than women to develop meth use disorder, though women who do develop it often have a more severe course. Men more commonly report initiating meth use for reasons related to socialization, euphoria, and peer context rather than the energy management and weight loss motivations more commonly reported by women. Men are also more likely than women to switch to another drug if meth is unavailable, suggesting a somewhat different relationship between the person and the specific drug.
This article addresses the patterns of meth use that are specifically relevant to men: the broader epidemiology, the distinct pattern of meth use in MSM populations including the chemsex context, the co-occurring health risks that disproportionately affect men with meth use disorder, particularly HIV and cardiovascular disease, the neurobiological sex differences in meth’s effects, and what the evidence shows about treatment considerations that are relevant to men specifically. Understanding these patterns helps men in recovery and those who support them approach treatment and recovery planning with accurate expectations.
Epidemiology: Who Uses Meth and How
According to SAMHSA’s 2022 National Survey on Drug Use and Health, approximately 2.7 million people aged 12 and older reported past-year methamphetamine use, with men consistently showing higher rates of use than women across most age groups. Men also account for the majority of meth-involved overdose deaths. According to CDC MMWR data covering January 2021 through June 2024, approximately 70% of stimulant-involved overdose deaths, including those involving methamphetamine, occurred among males.
Men’s meth use patterns tend to differ from women’s in route of administration, use setting, and social context. Smoking and intravenous injection are more common among men in certain populations; use in social and party contexts is more common. A PMC sex differences study in meth use practices found that men were more likely to report using meth in group or social settings, while women were more likely to use alone. Men more commonly report curiosity, peer influence, and euphoria as initiation motivations, while women more commonly report energy and weight management. These differences in use context and motivation have practical implications for how relapse triggers manifest and what peer support structures are most protective.
Men are also more likely to use meth in combination with other substances, particularly alcohol, cocaine, and polysubstance use patterns, and are less likely than women to seek treatment for meth use disorder despite higher overall rates of use. This treatment-seeking gap means that men with meth use disorder may accumulate more severe clinical presentations before engaging with care, and that barriers to treatment engagement in men warrant specific clinical attention.
Meth Use Among Gay, Bisexual, and Other Men Who Have Sex with Men (MSM)
A well-documented pattern in meth epidemiology is the disproportionately high prevalence of meth use among gay, bisexual, and other men who have sex with men. NIDA-funded research has consistently documented elevated meth use rates in MSM compared to the general male population, with the intersection of meth use, sexual behavior, and HIV creating a specific and serious public health context that requires clinical understanding.
The PMC NIDA-funded mSTUDY research on MSM in Los Angeles documented that as reported frequency of methamphetamine use increased among MSM, the odds of social adversity, sexual risk behaviors, sexually transmitted infections, and chronic clinical conditions all increased. Meth use in MSM is strongly associated with sexual disinhibition; the drug reduces inhibition and increases libido in ways that significantly elevate the likelihood of condomless sex with multiple partners, including casual and anonymous partners met through apps. This behavioral combination creates substantially elevated HIV acquisition risk for HIV-negative MSM and viral replication risk and treatment non-adherence for MSM living with HIV.
The “chemsex” or “party and play” context, the use of meth (and sometimes GHB/GBL or other drugs) specifically to enable extended sexual activity, often with multiple partners arranged through apps, is a specific use pattern concentrated in MSM populations. This pattern is clinically distinct from other meth use patterns: the drug is not used independently of sex, the sexual behavior is the organizing context of the use, and cessation of the drug use requires navigating the sexual behavior changes that accompany it. Treatment approaches that do not address the chemsex context directly, that treat meth as a standalone substance use disorder without addressing its sexual function, are incomplete for MSM whose use is primarily organized around this context.
MSM living with HIV who use meth face compounded medical risks. Meth use is associated with increased inflammation and viral replication in people with HIV, interference with antiretroviral therapy adherence, and accelerated disease progression. The NIDA-funded cohort study of MSM in Los Angeles found that meth use predicted greater viral load in people living with HIV, a finding with direct implications for the clinical urgency of meth treatment for HIV-positive MSM. Treatment for meth use disorder in this population is HIV care.
Minority Stress and Meth Use in MSM
Research applying minority stress theory to meth use in MSM documents that the chronic stress of stigma, discrimination, and homophobia functions as a risk factor for meth initiation and continued use. MSM of color face the intersectionality of racism and homophobia as simultaneous chronic stressors, and meth may be used as a coping mechanism for the distress these intersecting stressors produce. A New York City Department of Health and Mental Hygiene analysis of trends from 2004 to 2017 found that while methamphetamine use among White MSM decreased over the study period, use among Hispanic/Latino and Black MSM increased, a pattern consistent with the role of intersectional minority stress in driving use in these populations.
These patterns have direct treatment implications. MSM who use meth as a response to minority stress, to the chronic pain of navigating homophobia, racism, or the specific social challenges of LGBTQ+ life, need treatment that addresses the underlying stress drivers rather than only the substance use. A gay man who uses meth primarily to feel less anxious about sex, or to feel less shame about his body or his identity, is using meth for reasons that require affirmative clinical attention to identity and stigma, not only addiction treatment.
Neurobiological Sex Differences: What the Research Shows for Men
The neuroimaging literature documents sex-specific differences in how meth affects the brain. The PMC review of sex differences in SUD neurobiology documents that acute exposure to amphetamine produces a greater striatal level of dopamine (dopamine activity specifically in the striatum, the brain region central to reward, motivation, and habit formation) in males compared to females, and that ultrasound imaging of the midbrain in people with meth use history found that dopamine-rich region enlargement was greater in males than females. These sex-specific neurobiological differences may contribute to the different patterns of use severity, relapse risk, and recovery trajectory between men and women.
Men’s greater initial dopamine response to meth may contribute to the more rapid and intense reinforcement of meth use in men, explaining in part why men represent the larger share of heavy and long-duration users. The neurobiological recovery literature, while not always sex-stratified, is primarily drawn from male populations, which means the PET imaging findings on DAT recovery and brain metabolic recovery most directly describe what recovery looks like neurologically in men, even when that is not explicitly stated.
Co-Occurring Health Risks Disproportionately Affecting Men
Several health risks are disproportionately concentrated in men with meth use disorder:
Cardiovascular disease. Meth is a potent cardiovascular stimulant, and the cardiovascular burden of heavy meth use is significant: elevated heart rate, elevated blood pressure, arrhythmias, and the direct toxic effects of meth on cardiac tissue. Men, who already have higher baseline cardiovascular risk than women of the same age, face compounded cardiovascular risk from meth use. Meth-associated cardiomyopathy (structural damage to the heart muscle from meth toxicity), pulmonary hypertension, and elevated stroke risk are documented in the literature. Men with significant meth use histories should have cardiovascular evaluation as a routine component of recovery health care.
HIV and sexually transmitted infections. While HIV risk from meth use affects both men and women, the specific epidemiological intersection of meth use and HIV is most pronounced in MSM. The behavioral disinhibition from meth, combined with the HIV exposure risk in networks where prevalence is elevated, creates a level of HIV risk in MSM who use meth that is not replicated in other male populations. For heterosexual men who use meth via injection, shared needle risk for HIV and hepatitis C is the primary infectious disease concern.
Criminal justice involvement. Men with meth use disorder have higher rates of criminal justice involvement than women with the same disorder, including higher rates of incarceration, which creates specific barriers to treatment access, treatment continuity, and recovery support. Meth-related criminal charges in men are more likely to involve distribution, manufacture, or property offenses in addition to possession; these carry more serious legal consequences and create more significant post-incarceration barriers to employment and housing than possession charges alone.
Polysubstance use. Men with meth use disorder are more likely than women to have co-occurring alcohol use disorder or other substance use disorders. The polysubstance context complicates treatment, both in the clinical management of multiple substance withdrawals and in the relapse prevention work, which must address multiple trigger systems rather than only meth-specific triggers. Treatment programs should assess for and address co-occurring substance use disorders rather than focusing solely on the primary presenting substance.
Treatment Considerations Specific to Men
The treatment literature on sex differences in meth outcomes is, in general, less developed for men than for women, largely because the standard addiction treatment model was built on predominantly male samples, and men’s needs were implicitly treated as the default. But the evidence does identify several considerations relevant to men specifically:
Treatment engagement and retention. Men are less likely than women to initiate treatment for meth use disorder and are more likely to delay seeking help until later stages of severity. Barriers to treatment seeking in men include stigma around help-seeking, the association of substance use treatment with weakness or failure in cultural frameworks that prize self-sufficiency, and lower rates of social pressure to seek treatment. Men in meth recovery often describe the decision to seek treatment as having required either a severe external crisis or the influence of a specific person in their life, suggesting that targeted outreach and strong peer engagement at the point of treatment initiation are particularly important for men.
Addressing the MSM chemsex context. For gay, bisexual, and other MSM for whom meth use is primarily organized around sexual behavior, treatment that does not address the sexual dimensions of use is incomplete. Effective treatment for chemsex-associated meth use includes explicit discussion of the function meth serves in sexual contexts, development of alternative approaches to sexual activity and intimacy that do not require the drug, and affirmative clinical attention to identity, shame, and the social contexts in which the sexual use is occurring. MSM-specific treatment programs and affirming clinicians who understand the chemsex context are better positioned to provide this care than general addiction treatment programs without LGBTQ+ competency.
Contingency management effectiveness. Contingency management, the most evidence-supported behavioral treatment for meth use disorder, has demonstrated effectiveness in both general meth populations and specifically in MSM populations. A NIDA-funded contingency management study in MSM found that contingency management nearly doubled the rate of abstinence among men who have sex with men and use methamphetamine, the most robust treatment finding available for this population.
Addressing masculinity and help-seeking shame. Clinical programs that explicitly address the cultural dimensions of help-seeking for men, the shame associated with admitting vulnerability, the associations between seeking treatment and perceived weakness, create conditions in which men can engage more fully with the therapeutic process. This means engaging honestly with the cultural contexts that shaped how the person experiences addiction and recovery.
Professional Perspective
The clinical blind spot in treating men with meth use disorder is assuming that the generic addiction treatment model, built largely on male samples, is therefore adequate for men without modification. It is not. Men with meth use disorder have specific patterns of use, specific co-occurring risks, specific barriers to treatment initiation, and, for the substantial population of MSM who use meth in the chemsex context, specific treatment needs that require LGBTQ+-affirming care and explicit attention to the function meth serves in sexual behavior. The treatment gap for MSM is particularly acute: meth use disproportionately affects this population, the intersection of meth use and HIV creates clinical urgency, and the treatment system has historically underserved MSM both because of limited LGBTQ+-affirmative care capacity and because the chemsex context requires clinical sophistication that general addiction treatment programs frequently lack. Addressing this gap requires clinicians who understand the chemsex context, treatment programs with genuine LGBTQ+ competency, and explicit integration of HIV care with addiction treatment for MSM living with HIV. This is a public health gap that needs closing.
“Men are more likely than women to use almost all types of illicit drugs, and illicit drug use is more likely to result in emergency department visits or overdose deaths for men than for women. […] Research has shown that women often use drugs differently, respond to drugs differently, and can have unique obstacles to effective treatment as simple as not being able to find child care or being prescribed treatment that has not been adequately tested on women.”
What This Means When Looking for Treatment
For gay, bisexual, and other men who have sex with men, ask specifically whether a treatment program has genuine LGBTQ+-affirmative clinical capacity and whether clinicians have experience addressing the chemsex context. A program that has never heard the term “chemsex” or “party and play” is not equipped to treat MSM for whom meth use is primarily organized around sexual behavior. For all men, ask whether the program addresses co-occurring substance use disorders, whether cardiovascular health evaluation is part of the intake process for men with heavy meth use histories, and whether the program has experience engaging men who have significant cultural resistance to help-seeking.
Conclusion
Men represent the majority of people with meth use disorder and the majority of meth-involved overdose deaths. Men’s meth use patterns differ from women’s in initiation context, use setting, route of administration, and willingness to switch to alternative substances. Among gay, bisexual, and other MSM, meth use disproportionately occurs in the chemsex context, organized around sexual behavior in ways that create specific HIV risk, require specific treatment approaches, and demand LGBTQ+-affirming clinical care. Minority stress from homophobia and racism is a documented risk factor for meth use in MSM of color. Neurobiological sex differences include greater acute dopamine response to meth in males. Co-occurring risks disproportionate in men include cardiovascular disease, HIV and STIs in MSM, criminal justice involvement, and polysubstance use. Treatment considerations specific to men include addressing treatment initiation barriers tied to help-seeking stigma, the chemsex context for MSM, contingency management as the most evidence-supported treatment with documented effectiveness in MSM specifically, and the cultural dimensions of help-seeking for men. Recovery from meth is fully achievable for men, and the treatment conditions that make it most likely are those that address these specific patterns rather than assuming the general treatment model is adequate.